Real-life incidence of thrombotic events in leukemia patients treated with ponatinib

Am J Hematol. 2022 Sep;97(9):E350-E352. doi: 10.1002/ajh.26645. Epub 2022 Jul 12.

Authors

Affiliations

¹ Division of Pharmacy, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 35759571
DOI: 10.1002/ajh.26645

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / adverse effects
Humans
Imidazoles / adverse effects
Incidence
Leukemia*
Protein Kinase Inhibitors / adverse effects
Pyridazines* / adverse effects

Substances

Antineoplastic Agents
Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib